Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Related Articles by Review for PubMed (Select 8417384)

1.
3.
4.

Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects.

Vezina P, Mohr E, Grimes D.

Can J Neurol Sci. 1992 Feb;19(1 Suppl):142-6. Review.

PMID:
1571860
6.

Neuroprotection by anti-oxidant strategies in Parkinson's disease.

LeWitt PA.

Eur Neurol. 1993;33 Suppl 1:24-30. Review.

PMID:
8375428
7.

R-(-)-deprenyl and parkinsonism.

Yahr MD.

J Neural Transm Suppl. 1987;25:5-12. Review.

PMID:
3123605
8.
9.

Selegiline for Alzheimer's disease.

Birks J, Flicker L.

Cochrane Database Syst Rev. 2003;(1):CD000442. Review.

PMID:
12535396
10.
11.

Neuroprotective clinical strategies for Parkinson's disease.

Shoulson I.

Ann Neurol. 1992;32 Suppl:S143-5. Review.

PMID:
1510374
12.

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Fahn S; Parkinson Study Group.

J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. Review.

PMID:
16222436
13.

Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

Bryson HM, Milne RJ, Chrisp P.

Pharmacoeconomics. 1992 Aug;2(2):118-36. Review.

PMID:
10146952
14.

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Fernandez HH, Chen JJ.

Clin Neuropharmacol. 2007 May-Jun;30(3):150-68. Review.

PMID:
17545750
15.

Monoamine oxidase B inhibitors for early Parkinson's disease.

Macleod AD, Counsell CE, Ives N, Stowe R.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. Review.

PMID:
16034956
16.

[History of deprenyl--the first selective inhibitor of monoamine oxidase type B].

Knoll J.

Vopr Med Khim. 1997 Nov-Dec;43(6):482-93. Review. Russian.

PMID:
9503565
17.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk